Associate Professor, Medicine, UCSD School of Medicine
Internal Medicine
Dr. David L. Wyles, MD
|
|
Give Review
David L. Wyles, MD is an expert in the field of Internal Medicine. He graduated from Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine is ranked 19 in research and 29 in primary care medicine He has 1 awards "CMS Meaningful Use Stage 1 Certification". David L. Wyles is a published MD. He has 30 publications published. The most current publication "Regimens for Patients Coinfected with Human Immunodeficiency Virus." He is registered with Medicare.
Publications
- Regimens for Patients Coinfected with Human Immunodeficiency Virus.
- Functional conservation despite structural divergence in ligand-responsive RNA switches.
- IP-10 Kinetics in Treatment-Naïve Versus -Experienced Patients Receiving Interferon-Free Hepatitis C Virus Therapy: Implications for the Innate Immune Response.
- Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
- Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV- Infected Adults: A Randomized, Double-Blind, Phase 1b Study.
- All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naive Patients with Genotype 1 HCV Infection.
- High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen.
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection.
- Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
- Hepatitis C virus drug resistance: implications for clinical management.
- Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection.
- Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment.
- Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: Inhibitors of hepatitis C virus and HIV-1 replication.
- Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials.
- Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection.
- Rong's numbers: accelerating progress in HCV therapeutic research.
- Conformational inhibition of the hepatitis C virus internal ribosome entry site RNA.
- Alkoxyalkyl esters of 9-(s)-(3-hydroxy-2-phosphonomethoxypropyl) adenine are potent and selective inhibitors of hepatitis B virus (HBV) replication in vitro and in HBV...
- The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A...
- Hepatitis virus coinfection in the Strategic Management of Antiretroviral Therapy (SMART) study: a marker for nonliver, non-opportunistic disease mortality.
- Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.
- 3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication.
- Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets.
- Development of herpes simplex virus disease in patients who are receiving cidofovir.
- Abacavir pharmacokinetics in hepatic dysfunction.
- Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
- A modular approach to synthetic RNA binders of the hepatitis C virus internal ribosome entry site.
- Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
- The Hepatitis C Cascade of Care among HIV Infected Patients: A Call to Address Ongoing Barriers to Care.
Schools
Northwestern Center Feinberg School of Medicine
Doctors Specialties
- Infectious Disease Medicine
- Internal Medicine
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Colorado -
Northwestern University Feinberg School of Medicine
Drug Facts
| NPI NUMBER | 1548296775 | |
| NPPES Provider LastName | WYLES | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 921038201 | |
| NPPES Provider State | CA | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 36.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1548296775 |
| Last Name Of The Provider | WYLES |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Aaron D. Lewis, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. David M. Shaw, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Natalie H. Garcia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anna P. Quan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Satish A. Eraly, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Michelle M. Zolghadr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Calyani Ganesan, MD |
|
|
Dr. Michael G. Ziegler, MD |
|
Dr. Noli A. Cava, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher M. O'Brien, MD |
|
|
Dr. Roger A. Bitar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cathy L. Logan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven Oppenheim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kalpana Natrajan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven E. Gardner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John K. Chau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen H. Waterman, MD |